“Cellular and Humoral Immunogenicity of ADMVA, a Clade C/B MVA-Based HIV-1 Candidate Vaccine, in Healthy Volunteers”, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.,
“Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines”, J Infec Dis, vol. 177, pp. 310-319, 1998.
“A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with Rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers”, J Infec Dis, vol. 180, pp. 290-8, 1999.,
“Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults”, J Infec Dis, vol. 177, pp. 1230-46, 1998.,
“Immunization with envelope MN rap 120 vaccine in human immunodeficiency virus infected pregnant women”, J Infec Dis, vol. 180, pp. 1080-8, 1999.,
“Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials”, Vaccine, vol. 21-22, pp. 2933-2947, 2003.,